Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FluBuATG Conditioning in Allogeneic Stem Cell Transplant
NCT02916979Phase 1Completed
- Sponsor
- Dartmouth Health
- Start
- Sep 2016
- Primary completion
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of fludarabine, busulfan and antithymocyte globulin rabbit in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 7 more, sponsored by Dartmouth Health. Primary endpoint: Number of patients who are surviving at 100-Days post-transplant. Started Sep 2016; status: completed.
02
Drugs
fludarabinebusulfanantithymocyte globulin rabbit
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02916979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916979.